Toxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem.

TitleToxicity evaluation of convection-enhanced delivery of small-molecule kinase inhibitors in naïve mouse brainstem.
Publication TypeJournal Article
Year of Publication2015
AuthorsZhou Z, Ho SL, Singh R, Pisapia DJ, Souweidane MM
JournalChilds Nerv Syst
Volume31
Issue4
Pagination557-62
Date Published2015 Apr
ISSN1433-0350
KeywordsAnimals, Animals, Newborn, Brain Stem, Cell Line, Tumor, Cell Proliferation, Convection, Dasatinib, Dose-Response Relationship, Drug, Drug Delivery Systems, Everolimus, Glioma, Intracranial Hemorrhages, Mice, Phosphorylcholine, Protein Kinase Inhibitors, Time Factors
Abstract

PURPOSE: Diffuse intrinsic pontine gliomas (DIPGs) are inoperable and lethal high-grade gliomas lacking definitive therapy. Platelet-derived growth factor receptor (PDGFR) and its downstream signaling molecules are the most commonly overexpressed oncogenes in DIPG. This study tested the effective concentration of PDGFR pathway inhibitors in cell culture and then toxicity of these small-molecule kinase inhibitors delivered to the mouse brainstem via convection-enhanced delivery (CED) for potential clinical application.

METHODS: Effective concentrations of small-molecule kinase inhibitors were first established in cell culture from a mouse brainstem glioma model. Sixteen mice underwent CED, a local drug delivery technique, of saline or of single and multidrug combinations of dasatinib (2 M), everolimus (20 M), and perifosine (0.63 mM) in the pons. Animals were kept alive for 3 days following the completion of infusion.

RESULTS: No animals displayed any immediate or delayed neurological deficits postoperatively. Histological analysis revealed edema, microgliosis, acute inflammation, and/or axonal injury in the experimental animals consistent with mild acute drug toxicity.

CONCLUSIONS: Brainstem CED of small-molecule kinase inhibitors in the mouse did not cause serious acute toxicities. Future studies will be necessary to evaluate longer-term safety to prepare for potential clinical application.

DOI10.1007/s00381-015-2640-7
Alternate JournalChilds Nerv Syst
PubMed ID25712742
Related Faculty: 
David Pisapia, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700